Clinical value of atezolizumab plus bevacizumab for first-line unresectable hepatocellular carcinoma (HCC): A network meta-analysis.

被引：0
|
作者：
Vogel, Arndt
Rimassa, Lorenza
Sun, Hui-Chuan
Abou-Alfa, Ghassan K.
El-Khoueiry, Anthony B.
Pinato, David James
Daigl, Monica
Alvarez, Javier Sanchez
Orfanos, Panos
Leibfried, Michael
Zumofen, Marie-Helene Blanchet
Gaillard, Vincent
Merle, Philippe
机构：
[1] Hannover Med Sch, Hannover, Germany
[2] Humanitas Univ, Pieve Emanuele, Italy
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Weill Cornell Med Coll, New York, NY USA
[6] USC Norris Comprehens Canc Ctr, Keck Sch Med, Div Med Oncol, Los Angeles, CA USA
[7] Imperial Coll London, Dept Surg & Canc, London, England
[8] F Hoffmann La Roche Ltd, Basel, Switzerland
[9] Genentech Inc, San Francisco, CA 94080 USA
[10] Hop Croix Rousse, Dept Hepatol, Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4585
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Atezolizumab plus bevacizumab for advanced, unresectable hepatocellular carcinoma
    Tsilimigras, Diamantis I.
    Moris, Dimitrios
    JOURNAL OF BUON, 2021, 26 (02): : 637 - 638
  • [22] First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
    Chiang, Chi-Leung
    Chan, Sik-Kwan
    Lee, Shing-Fung
    Choi, Horace Cheuk-Wai
    CANCERS, 2021, 13 (05) : 1 - 13
  • [23] Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib
    Hiraoka, Atsushi
    Kumada, Takashi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Shimada, Noritomo
    Kawata, Kazuhito
    Naganuma, Atsushi
    Kosaka, Hisashi
    Shibata, Hiroshi
    Aoki, Tomoko
    Tanaka, Takaaki
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Iijima, Hiroko
    Kaibori, Masaki
    Hiasa, Yoichi
    Kudo, Masatoshi
    CANCER MEDICINE, 2023, 12 (01): : 325 - 334
  • [24] First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis
    Chan, S.
    Chiang, C.
    Lee, S.
    Choi, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S97 - S97
  • [25] Atezolizumab plus bevacizumab versus lenvatinib as first-line therapy for advanced hepatocellular carcinoma: A systematic review and meta-analysis
    Giri, Suprabhat
    Angadi, Sumaswi
    Vaidya, Arun
    Singh, Ankita
    Roy, Akash
    Sundaram, Sridhar
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 228 - 235
  • [26] Bayesian Analysis Supports Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Brandi, Giovanni
    LIVER CANCER, 2022, 11 (02) : 180 - 181
  • [27] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
    Hiraoka, Atsushi
    Kumada, Takashi
    Tada, Toshifumi
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    Hatanaka, Takeshi
    Ohama, Hideko
    Nouso, Kazuhiro
    Morishita, Asahiro
    Tsutsui, Akemi
    Nagano, Takuya
    Itokawa, Norio
    Okubo, Tomomi
    Arai, Taeang
    Imai, Michitaka
    Koizumi, Yohei
    Nakamura, Shinichiro
    Joko, Kouji
    Iijima, Hiroko
    Hiasa, Yoichi
    Kudo, Masatoshi
    CANCER REPORTS, 2022, 5 (02)
  • [28] Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ plus BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
    Monzon, M. E. Reig
    Caro, N. Luque
    Bruix, J.
    Martin, C. Gomez
    Sangro, B.
    Varela, J. Sastre
    Tres, J. M. Ordonez
    Argemi, J.
    Lopez, R. Perez
    Candela, M. P. Torres
    Lledo-Navarro, J. L.
    Pena, A. M. Matilla
    Montero, J-L.
    Cid, R. A. Pazo
    Varela, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S606 - S607
  • [29] Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab
    Rimini, Margherita
    Stefanini, Bernardo
    Tada, Toshifumi
    Suda, Goki
    Shimose, Shigeo
    Kudo, Masatoshi
    Finkelmeier, Fabian
    Yoo, Changhoon
    Presa, Jose
    Amadeo, Elisabeth
    Genovesi, Virginia
    De Grandis, Maria Caterina
    Iavarone, Massimo
    Marra, Fabio
    Foschi, Francesco
    Tamburini, Emiliano
    Rossari, Federico
    Vitiello, Francesco
    Bartalini, Linda
    Solda, Caterina
    Tovoli, Francesco
    Vivaldi, Caterina
    Lonardi, Sara
    Silletta, Marianna
    Kumada, Takashi
    Sakamoto, Naoya
    Iwamoto, Hideki
    Aoki, Tomoko
    Himmelsbach, Vera
    Montes, Margarida
    Hiraoka, Atsushi
    Sho, Takuya
    Niizeki, Takashi
    Nishida, Naoshi
    Steup, Christoph
    Hirooka, Masashi
    Kariyama, Kazuya
    Tani, Joji
    Atsukawa, Masanori
    Takaguchi, Koichi
    Itobayashi, Ei
    Fukunishi, Shinya
    Tsuji, Kunihiko
    Ishikawa, Toru
    Tajiri, Kazuto
    Ochi, Hironori
    Yasuda, Satoshi
    Toyoda, Hidenori
    Ogawa, Chikara
    Nishimura, Takashi
    LIVER INTERNATIONAL, 2024, 44 (05) : 1108 - 1125
  • [30] Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma
    Nakabori, Tasuku
    Higashi, Sena
    Abe, Yutaro
    Mukai, Kaori
    Ikawa, Toshiki
    Konishi, Koji
    Maeda, Noboru
    Nakanishi, Katsuyuki
    Hasegawa, Shinichiro
    Wada, Hiroshi
    Ohkawa, Kazuyoshi
    CURRENT ONCOLOGY, 2024, 31 (03) : 1543 - 1555
12345